Buscar Close Search
Buscar Close Search
Page Menu

"Speaking of Vitiligo..."

I am a physician-scientist who focuses my clinical and research efforts on vitiligoI am a physician-scientist who focuses my clinical and research efforts on vitiligo, and therefore I think about this disease a lot – all the time, in fact. Therefore I thought it would be helpful to share my thoughts with others who are interested in vitiligo as well, particularly the patients who suffer from it and their loved ones. I want to make clear that while I am affiliated with many vitiligo organizations, my comments in this blog are my own, and do not reflect the opinions of those organizations. In addition, my research is largely focused on finding new treatments, and ultimately a cure, for vitiligo. This work is supported by a number of sources, including pharmaceutical companies, which by definition creates potential conflicts of interest. In full disclosure, here is a list of our vitiligo research supporters. Please know that, to the best of my ability, all of my comments are unbiased reflections of my understanding of vitiligo as both a physician and scientist. I do not permit advertisements on my website, and do not endorse companies or products that may advertise on other sites that may be referenced here.

  • vitiligo-clinical-trial-results.png

    Cutting-Edge Developments in Vitiligo Clinical Trials

  • Vitiligo JAK Inhibitor Update

    Ever since the report from Yale published about a vitiligo patient who improved after using Xeljanz (tofacitinib) and then our report about Jakafi (ruxolitinib) in another patient, there has been

    Read more
  • Ruxolitinib (Jakafi) is a new drug that worked for a patient with vitiligo!

    We recently published a report about a vitiligo patient who quickly improved after taking ruxolitinib (Jakafi), a drug that inhibits Janus Kinases (JAKs), which are important for signals that tell

    Read more
  • Tofacitinib treatment for vitiligo

    Using tofacitinib in vitiligo on our research, which defined the IFN-γ signaling pathway as critical for vitiligo progression and maintenance. It supports our hypothesis that targeting this

    Read more